Comparison of the efficacy and safety of carbapenem versus other β-lactam antibiotics with anti-Pseudomonas aeruginosa activity in the initial treatment of febrile neutropenia: a target trial emulation using large-scale health insurance claims databa

Background Carbapenem resistance has recently become an issue, and carbapenem-sparing therapies have been adopted accordingly. For the initial treatment of febrile neutropenia (FN), carbapenems and other β-lactam antibiotics with anti- Pseudomonas aeruginosa ( P. aeruginosa ) activity are recommended. This study aimed to compare the efficacy and safety of initial treatment strategies using carbapenems versus cephalosporins with anti- P. aeruginosa activity (CEP) or piperacillin/tazobactam (PTZ) for FN. Methods Using the JMDC hospital-based database, we conducted a target trial comparing the strategy of initiating carbapenems with that of initiating CEP/PTZ for FN. Cancer patients who developed FN after initial chemotherapy and received targeted antibiotics between April 2014 and August 2025 were identified. Patients were classified into the carbapenem and CEP/PTZ groups based on the initial antibiotic selection. Stabilized inverse probability of treatment weighting based on propensity scores was used to adjust the balance of baseline patient characteristics. The primary endpoint was the 28-day mortality. Secondary endpoints included the antibiotic class-switching rate, treatment duration, addition of anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents, addition of antifungal agents, incidence of Clostridioides difficile infection (CDI), and therapeutic use of granulocyte colony-stimulating factor (G-CSF). Results Among 4468 patients in the study (CEP/PTZ group, 3791; carbapenem group, 677), no significant difference in 28-day mortality was observed between the groups (HR, 1.164; 95% CI, 0.783–1.732; p = 0.453). Antibiotic class switching was significantly more frequent in the CEP/PTZ group than in the carbapenem group (23.6% vs. 12.4%; sHR, 0.411; 95% CI, 0.320–0.527; p < 0.001), whereas the addition of anti-MRSA agents was more frequent in the carbapenem group than in the CEP/PTZ group (15.9% vs. 11.5%; sHR, 1.544; 95% CI, 1.173–2.031; p = 0.002). No significant differences were observed in the treatment duration, addition of antifungal agents, incidence of CDI, or therapeutic use of G-CSF. Conclusions No significant difference in 28-day mortality was observed between the strategy of initiating carbapenems and that of initiating CEP/PTZ, although antibiotic class switching was more frequent in the latter. From the perspective of carbapenem-sparing, initiating CEP/PTZ with escalation when clinically indicated may be a reasonable option for the initial treatment of FN.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Health Care and Sciences
Published
2026-11-19
DOI
https://doi.org/10.1186/s40780-026-00650-7
Primary Topic
Neutropenia and Cancer Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparison of the efficacy and safety of carbapenem versus other β-lactam antibiotics with anti-Pseudomonas aeruginosa activity in the initial treatment of febrile neutropenia: a target trial emulation using large-scale health insurance claims databa

Yuichi Muraki, Ryo Inose, Kanako Mizuno
1 links
Journal of Pharmaceutical Health Care and Sciences
Neutropenia and Cancer Infections
article

Comparison of the efficacy and safety of carbapenem versus other β-lactam antibiotics with anti-Pseudomonas aeruginosa activity in the initial treatment of febrile neutropenia: a target trial emulation using large-scale health insurance claims databa

Yuichi Muraki, Ryo Inose, Kanako Mizuno
article en

Abstract

Background Carbapenem resistance has recently become an issue, and carbapenem-sparing therapies have been adopted accordingly. For the initial treatment of febrile neutropenia (FN), carbapenems and other β-lactam antibiotics with anti- Pseudomonas aeruginosa ( P. aeruginosa ) activity are recommended. This study aimed to compare the efficacy and safety of initial treatment strategies using carbapenems versus cephalosporins with anti- P. aeruginosa activity (CEP) or piperacillin/tazobactam (PTZ) for FN. Methods Using the JMDC hospital-based database, we conducted a target trial comparing the strategy of initiating carbapenems with that of initiating CEP/PTZ for FN. Cancer patients who developed FN after initial chemotherapy and received targeted antibiotics between April 2014 and August 2025 were identified. Patients were classified into the carbapenem and CEP/PTZ groups based on the initial antibiotic selection. Stabilized inverse probability of treatment weighting based on propensity scores was used to adjust the balance of baseline patient characteristics. The primary endpoint was the 28-day mortality. Secondary endpoints included the antibiotic class-switching rate, treatment duration, addition of anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents, addition of antifungal agents, incidence of Clostridioides difficile infection (CDI), and therapeutic use of granulocyte colony-stimulating factor (G-CSF). Results Among 4468 patients in the study (CEP/PTZ group, 3791; carbapenem group, 677), no significant difference in 28-day mortality was observed between the groups (HR, 1.164; 95% CI, 0.783–1.732; p = 0.453). Antibiotic class switching was significantly more frequent in the CEP/PTZ group than in the carbapenem group (23.6% vs. 12.4%; sHR, 0.411; 95% CI, 0.320–0.527; p < 0.001), whereas the addition of anti-MRSA agents was more frequent in the carbapenem group than in the CEP/PTZ group (15.9% vs. 11.5%; sHR, 1.544; 95% CI, 1.173–2.031; p = 0.002). No significant differences were observed in the treatment duration, addition of antifungal agents, incidence of CDI, or therapeutic use of G-CSF. Conclusions No significant difference in 28-day mortality was observed between the strategy of initiating carbapenems and that of initiating CEP/PTZ, although antibiotic class switching was more frequent in the latter. From the perspective of carbapenem-sparing, initiating CEP/PTZ with escalation when clinically indicated may be a reasonable option for the initial treatment of FN.

Journal of Pharmaceutical Health Care and Sciences
Kyoto Pharmaceutical University (JP)
Good health and well-being
Neutropenia and Cancer Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon